Nov 22, 2011
I know what you’re thinking. “The government already profits off of medical marijuana through forfeiture laws every time it raids a dispensary and takes all its cash and equipment without ever pressing charges.” Well, yes. You’re right. But never underestimate our government’s ability to find new and exciting ways to display its hypocrisy.
As we told you on our blog last week, the U.S. government owns a patent on the use of some of marijuana’s components as antioxidant and neuroprotectant. This is despite the fact that it also classifies marijuana as a Schedule I substance with “no accepted medical use” and a “high potential for abuse.”
Late last week, the U.S. government published a notice in the Federal Register, where the government publishes all potential regulatory actions so that the public can provide comments, stating that it was considering licensing its rights to that patent to a company called KannaLife Sciences. The purpose of the license is: “[t]he development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy ...”
How a substance with “no accepted medical use” could be used to treat anything is a mystery. Of course, you and I know better. We know that there are hundreds of studies, including the gold-standard “double-blind, placebo-controlled” variety, showing marijuana and its components are effective in treating myriad ailments. Sadly, we haven’t yet begun to grasp its full potential because of federal obstruction of research (PDF) into marijuana’s medical potential, even for troops returning from Iraq and Afghanistan.
So good luck Kannalife, you’re going to need it. The same government that’s licensing patent rights with one hand is busy blocking the research you’ll need to do with the other. It’s called hypocrisy.